Pharmacogenetic challenges for the health care system

Health Affairs

Volumn 21, Issue 4, 2002, Pages 155-167

  Robertson, John A ^a   Brody, Baruch ^b   Buchanan, Allen ^c   Kahn, Jeffrey ^d,e   McPherson, Elizabeth ^f  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Center for Bioethics

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; GENETIC SCREENING; HEALTH CARE DELIVERY; HUMAN; LEGAL ASPECT; MEDICAL EDUCATION; ORGANIZATION AND MANAGEMENT; PHARMACOGENETICS; PRIVACY; UNITED STATES;

DELIVERY OF HEALTH CARE; DRUG INDUSTRY; EDUCATION, MEDICAL; FINANCING, GOVERNMENT; GENETIC SCREENING; HUMANS; PHARMACOGENETICS; PRIVACY; UNITED STATES;

EID: 0036635332     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.21.4.155     Document Type: Article

References (11)

1. U.E. Reinhardt, "Perspectives on the Pharmaceutical Industry," Health Affairs (Sep/Oct 2000): 136-149.
2. A. Roses, "Pharmacogenetics and Future Drug Development and Delivery," Lancet 355, no. 9212 (2000): 1358-1361.
3. The term pharmacogenomics is sometimes used interchangeably with pharmacogenetics. In this paper we use the latter because of our focus on individual genotypic variation in drug response, rather than the genomewide correlations that occur in pharmacogenomic research.
4. An excellent scientific overview of the field is provided by W.E. Evans and J.A. Johnson, "Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response," Annual Review of Genomics and Human Genetics 2 (2001): 9-39.
5. Ibid.
6. D.V. Exner et al., "Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction," New England Journal of Medicine 344, no. 18 (2001): 1351-1357; and A.J.J. Wood, "Racial Differences in the Response to Drugs - Pointers to Genetic Differences," New England Journal of Medicine 344, no. 18 (2001): 1393-1395.
7. D.V. Exner et al., "Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction," New England Journal of Medicine 344, no. 18 (2001): 1351-1357; and A.J.J. Wood, "Racial Differences in the Response to Drugs - Pointers to Genetic Differences," New England Journal of Medicine 344, no. 18 (2001): 1393-1395.
8. Editors, "Trial for Ethnic Drug," Science (30 March 2001): 2547.
9. Orphan Drug Act, P.L. 97-414, 96 Stat. 2049 (1982) (codified as amended at 21 U.S. Code 360aa-360ce (1994), 26 U.S. Code 45C (Supp. II 1994), 42 U.S. Code 236 (1994).
10. A.K. Rai, "Pharmacogenetic Interventions, Orphan Drugs, and Distributive Justice: The Role of Cost-Benefit Analysis," Journal of Social Philosophy and Policy 19, no. 2 (2002): 246-270.
11. Collins, "Shattuck Lecture - Medical and Societal Consequences of the Human Genome Project."